Research across Hormone Receptor-Positive Breast Cancer
Related studies from across the Hormone Receptor-Positive Breast Cancer family.
Carboplatin addition to standard chemotherapy improves event-free survival in early-stage triple-negative breast cancer
Adding carboplatin improves survival for triple-negative breast cancer
This phase III trial evaluated the addition of carboplatin to a doxorubicin and cyclophosphamide regimen followed by a taxane in patients wi…
Adding carboplatin to standard chemotherapy improves event-free survival for women with early-stage triple-negative breast cancer.
Pembrolizumab reduces death risk by 34% in early-stage triple-negative breast cancer patients
New Treatment Options Improve Survival for Patients with Triple Negative Breast Cancer
This meta-analysis of 3133 patients evaluates the efficacy of pembrolizumab and capecitabine in early-stage triple-negative breast cancer. T…
Doctors are finding that combining specific drugs can significantly improve survival rates and keep cancer from returning in early-stage pat…
Sacituzumab tirumotecan shows manageable safety profile in metastatic triple-negative breast cancer
Trial shows manageable safety for triple-negative breast cancer treatment
This randomized controlled trial post-hoc exploratory analysis of 262 patients with metastatic triple-negative breast cancer evaluated the s…
A new analysis shows that patients with triple-negative breast cancer can manage common side effects during treatment.
Immune Checkpoint Inhibitors Combined With Chemotherapy Improve Pathological Complete Response in TNBC
Immunotherapy Combined With Chemotherapy Shows Higher Response Rates in TNBC
Combining immune checkpoint inhibitors with chemotherapy significantly improves pathological complete response rates in patients with triple…
Adding immunotherapy to chemotherapy may improve response rates for patients with early-stage or high-risk triple-negative breast cancer.
Tumor necrosis-related fever may occur during neoadjuvant chemoimmunotherapy for metaplastic breast carcinoma
Case Report Shows Tumor Necrosis Fever in Breast Cancer Treatment
This case report describes a patient with triple-negative breast cancer receiving neoadjuvant chemoimmunotherapy who experienced a tumor nec…
A single case study highlights how a persistent fever during chemotherapy may be caused by tumor necrosis rather than an infection.
RPN1 overexpression promotes immune evasion and treatment resistance in multiple malignancies including hepatocellular carcinoma
RPN1 Protein Linked to Worse Outcomes in Several Cancers
This systematic review examines the role of RPN1 in glioma, hepatocellular carcinoma, sarcoma, and triple-negative breast cancer. The author…
High levels of the RPN1 protein are linked to aggressive cancer features and help tumors hide from the body's immune system.
ICIs Boost pCR in Early Triple-Negative Breast Cancer
Immune drugs combined with chemotherapy improve results for triple-negative breast cancer
Adding immune checkpoint inhibitors to chemotherapy improves pathological complete response in early triple-negative breast cancer, with PD-…
Adding immune checkpoint inhibitors to chemotherapy significantly increases the chance of clearing cancer cells in triple-negative breast ca…
Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC
New data shows specific drug combinations improve triple-negative breast cancer outcomes
This network meta-analysis of 7,683 patients with early-stage triple-negative breast cancer (TNBC) evaluated various neoadjuvant treatment r…
New data shows that adding specific drugs like pembrolizumab or bevacizumab to standard chemotherapy can improve response rates for early-st…
Targeted therapy plus chemotherapy improves objective response and disease control rates in advanced TNBC
Targeted therapy plus chemotherapy improves response in triple-negative breast cancer
This systematic review and meta-analysis of 523 patients found that adding targeted therapy to chemotherapy for advanced triple-negative bre…
Adding targeted therapy to chemotherapy may improve how tumors respond in patients with advanced triple-negative breast cancer.
Adjuvant CDK4/6 inhibitors improve invasive Disease-Free Survival regardless of patient menopausal status
CDK4/6 inhibitors show consistent results for both pre and postmenopausal women
This meta-analysis of 17,748 patients with HR+ and HER2-negative early breast cancer found that adjuvant CDK4/6 inhibitors improved invasive…
New data suggests that a specific type of breast cancer treatment works effectively regardless of whether a patient has reached menopause.
Neoadjuvant immune checkpoint inhibitors plus chemotherapy increase pathological complete response in early-stage triple-negative breast cancer
Immune checkpoint inhibitors improve response in triple-negative breast cancer
This meta-analysis of 3,377 patients found that neoadjuvant immune checkpoint inhibitors combined with chemotherapy significantly increased …
Adding immune checkpoint inhibitors to chemotherapy helps more patients with early-stage triple-negative breast cancer achieve a complete re…
Chemokine networks regulate triple-negative breast cancer tumor microenvironment but clinical translation remains limited
Chemokine Targets Show Promise in Lab but Face Clinical Hurdles
This systematic review examines the role of chemokine networks and targeted interventions in the triple-negative breast cancer immune microe…
New research highlights the role of chemokine networks in breast cancer, showing strong results in labs despite challenges in current clinic…